STOCK TITAN
  1. Home
  2. Sec-filings
  3. LXRX
  4. [Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity

Diane E. Sullivan converts 89,312 RSUs at Lexicon Pharmaceuticals (LXRX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lexicon Pharmaceuticals director Diane E. Sullivan reported the vesting and exercise of restricted stock units into common shares. On June 3, 2026, 89,312 restricted stock units converted into 89,312 shares of common stock at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase. Following this transaction, Sullivan directly owned 126,122 shares of common stock. Footnotes explain that each restricted stock unit represented a contingent right to receive one share and that the award vested in full on the first anniversary of its grant date.

Positive

  • None.

Negative

  • None.
Insider Sullivan Diane E.
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 89,312 $0.00 --
Exercise Common Stock 89,312 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 126,122 shares (Direct, null)
Footnotes (1)
  1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.
RSUs converted 89,312 shares Restricted stock units converting into common stock on June 3, 2026
Price per share $0.00 per share Stated price for conversion of restricted stock units
Shares held after 126,122 shares Total common shares directly owned by Diane E. Sullivan after transaction
Derivative positions remaining 0 RSUs from this grant Restricted stock units balance following full vesting and conversion
Restricted Stock Units financial
"The reported award consisted of 89,312 restricted stock units, each representing the right to receive one common share."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share of common stock."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sullivan Diane E.
(Last)(First)(Middle)
2445 TECHNOLOGY FOREST BLVD.
11TH FLOOR
(Street)
THE WOODLANDS TEXAS 77381
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/03/2026M89,312A$0126,122D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$006/03/2026M89,312 (1) (2)Common Stock89,312$00D
Explanation of Responses:
1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
2. Each restricted stock unit represents a contingent right to receive one share of common stock.
/s/ Diane E. Sullivan06/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Lexicon Pharmaceuticals (LXRX) report for Diane E. Sullivan?

Lexicon Pharmaceuticals reported that director Diane E. Sullivan acquired 89,312 common shares through the vesting and exercise of restricted stock units. This was compensation-related, not an open-market purchase or sale, and increased her directly held stake in the company.

How many Lexicon Pharmaceuticals shares does Diane E. Sullivan hold after this Form 4 filing?

After the reported transaction, Diane E. Sullivan directly holds 126,122 shares of Lexicon Pharmaceuticals common stock. This total reflects the addition of 89,312 shares acquired through the vesting and conversion of restricted stock units on June 3, 2026.

Was the Lexicon Pharmaceuticals (LXRX) Form 4 transaction a market buy or sell?

The Form 4 shows no open-market buy or sell. Instead, it records the vesting and conversion of 89,312 restricted stock units into common shares at a stated price of $0.00 per share, reflecting stock-based compensation rather than trading activity.

What do the restricted stock unit footnotes mean in the Lexicon Pharmaceuticals Form 4?

The footnotes state that each restricted stock unit represented a contingent right to receive one common share and that 100% of the units vested on the first anniversary of the grant date. Upon vesting, 89,312 units converted into an equal number of common shares.

How large was the restricted stock unit award reported for Lexicon Pharmaceuticals director Diane E. Sullivan?

The reported award consisted of 89,312 restricted stock units, each representing the right to receive one common share. All 89,312 units vested and were converted into 89,312 shares of Lexicon Pharmaceuticals common stock in the transaction disclosed on the Form 4.